Stanley G. Miele
Chief Commercial Officer
Mr. Miele became our Chief Commercial Officer in October 2015. He had previously served as President of Sucampo Pharma Americas, LLC, since 2009 and Senior Vice President of Sales and Marketing since 2008. Mr. Miele joined Sucampo in 2006 as National Director of Sales and was subsequently promoted to Vice President of Sales.
Prior to joining Sucampo, Mr. Miele was the i-STAT Executive Sales Manager for Abbott Diagnostics, a division of global healthcare company Abbott Laboratories, from 2005 to 2006. From 2003 to 2005, he held a series of positions at Millennium Pharmaceuticals and at COR Therapeutics, prior to its acquisition by Millennium, including National Sales Director, Cardiology.
Mr. Miele began his career as a sales representative both at the Hospital Products Division of Abbott Laboratories, and at Syntex Labs.
Mr. Miele earned a bachelor’s degree in management communications from the University of Dayton.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.